Paper Details

  1. Home
  2. Paper Details

Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.

Author: , BargayJoan, BerlangaJoan, BrunetSalut, BuenoJavier, EsteveJordi, GranenaAlbert, GuardiaRamon, JuliáAntoni, MartíJosep M, MontserratEmili, RiberaJosep M, SierraJorge

Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

High-dose cytarabine is a good option for patients with t(8;21) acute myeloid leukemia. Autologous and allogeneic stem cell transplantation lead to similar leukemia-free survival in patients under 50 years old, but autologous SCT results are poor in older patients.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND OBJECTIVES: To evaluate a regimen of induction and consolidation chemotherapy, followed by a post-remission therapy which depended on age and cytogenetics, in patients with primary acute myeloid leukemia. DESIGN AND METHODS: Two hundred patients up to 60 years old received idarubicin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15339677

データ提供：米国国立医学図書館（NLM）

Tailoring Treatment for Primary Acute Myeloid Leukemia: A Multi-faceted Approach

The field of [acute myeloid leukemia (AML)] treatment is constantly evolving, seeking to improve patient outcomes through personalized approaches. This study presents the results of a [prospective multicenter trial] evaluating a specific regimen of [induction and consolidation chemotherapy] followed by [post-remission therapy], tailored based on age and cytogenetics. The researchers sought to assess the effectiveness of this multi-pronged strategy in patients with [primary AML], providing valuable insights into the impact of different treatment modalities on survival and leukemia-free survival (LFS).

Optimizing AML Treatment: A Personalized Approach

This study highlights the importance of [risk-adapted treatment] in AML. The researchers demonstrated that [high-dose cytarabine] was an effective option for patients with [favorable cytogenetics], while [allo-SCT] and [auto-SCT] showed similar LFS in younger patients. However, older patients with [auto-SCT] experienced poorer outcomes. These findings emphasize the need for a personalized approach to treatment, considering factors such as age, cytogenetics, and overall risk profile.

Improving Outcomes for AML Patients: A Collaborative Effort

If you or someone you know is diagnosed with [AML], it is crucial to seek prompt medical attention and engage in a collaborative dialogue with your healthcare team. Early diagnosis, personalized treatment plans, and ongoing monitoring are key to maximizing treatment outcomes and improving the quality of life for AML patients.

Dr.Camel's Conclusion

This study is a testament to the ongoing progress in AML treatment, emphasizing the power of personalized medicine. Like a careful caravan navigating a challenging desert terrain, we must adapt our approach to individual needs and utilize the best tools available to ensure a successful journey for our patients.

Date :
  1. Date Completed 2006-03-08
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

15339677

DOI: Digital Object Identifier

15339677

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.